Here’s what is known about Trump’s COVID-19 treatment – Science Magazine

President Donald Trump has maintained a steady schedule of campaign rallies, which may have exposed him to SARS-CoV-2.

By Jon CohenOct. 2, 2020 , 9:25 PM

Sciences COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.

This afternoon, the White House announced that President Donald Trump received an experimental antibody treatment after a test revealed he'sinfected with SARS-CoV-2. He reportedly has mild COVID-19 symptoms, including fever and congestion, and he was transferred to Walter Reed National Military Medical Center. Later, the president's medical team confirmed he had started a course of remdesivir, an antiviral drug shown to modestly help hospitalized COVID-19 patients.

What is the antibody cocktail Trump received?

Its a combination of two antibodies directed against a key protein of the virus that causes COVID-19, SARS-CoV-2. They bind to a region on the main surface spike protein that helps the virus attach to a receptor on human cells called angiotensin-converting enzyme 2 (ACE2). The targeted region is dubbed the receptor binding domain. One antibody comes from a human who had recovered from a SARS-CoV-2 infection; a B cell that makes the antibody was harvested from the persons blood and the genes for the immune protein isolated and copied. The other antibody is from a mouse, which was engineered to have a human immune system, that had the spike protein injected into it.

Are there any data showing that the cocktail works and is safe?

Experiments in both golden hamsters and rhesus macaque monkeys that intentionally were infected with SARS-CoV-2 showed that the cocktail could reduce viral levels and disease pathology.

Regeneron, the maker of the cocktail, earlier this week presented preliminary data from its ongoing clinical trial in people who tested positive for SARS-CoV-2 but were asymptomatic or, in the most extreme cases, had moderate diseasea group that would appear to mirror Trumps current condition. No serious safety concerns surfaced, and the treatment reduced viral load and shortened symptomatic disease in patients who did not have SARS-CoV-2 antibodies at the trials start. Its unclear whether the treatment can prevent severe disease, but there were hints that it might: Participants who received a placebo had more medical visits.

A separate trial is assessing the impact of the treatment on hospitalized COVID-19 patients, but Regeneron has yet to report any results from that study.

Do the preliminary clinical trial data match the presidents treatment scheme?

Not exactly. Trump received an 8-gram infusion of the treatment. Regenerons data showed that a 2.4-gram infusion worked as well as the higher dose at reducing SARS-CoV-2 levels in people. This was widely seen as good news because monoclonals are difficult and expensive to produce, and a lower dose means that more people ultimately can receive it.

Why did the president receive the higher dose of the antibodies?

Likely out of an abundance of caution by the presidents medical team, says George Yancopoulos, the co-founder and chief scientific officer of Regeneron. Yancopoulos does not directly know why Trump'sphysicians chose to use 8 grams, but says the companys data indicate theres very, very limited risk that the antibodies will cause harm at either dose. The higher dose might last longer, he said, and at some time points in the companys study, Regeneron did see trends suggesting that the higher dose more powerfully beats back the virusthe company used the amount of viral genetic material found with nose swabs as a proxy for SARS-CoV-2 levels in the entire body.

If I had to treat one patient, Id give the high dose, Yancopoulos says. From a societal point of view and the need to treat as many people as possible, Id give the lower dose.

Did Trump match the patients in the study who benefited from the treatment?

The Regeneron study found that the treatment only worked in people who did not have SARS-CoV-2 antibodies at the start of the study. It also worked best in people who had higher levels of the virus. Whether the president had those antibodies and a high viral load has not been made public. I couldnt speculate because it has to do with an individual patient, Yancopoulos says.

The memorandum from the presidents physician said Trump was receivingRegenerons polyclonal antibody cocktail. Are these antibodies polyclonal?

No. The treatment consisted of two monoclonal antibodiesmeaning each was produced by making identical copies, or clones, of an antibody gene in a single B cell. Polyclonal antibody cocktails refer to antibodies made by mixtures of B cells.

What was the regulatory mechanism that allowed the president to receive the experimental Regeneron antibodies?

The antibodies are typically only available to people who participate in clinical trials. Trump theoretically could have enrolled in the ongoing treatment study that reported preliminary data this week, but that trial randomly assigns half the participants to receive the antibodies; the other half serves as a control group and receives infusions of an inactive placebo. A U.S. Food and Drug Administration (FDA) regulation called expanded accesstechnically known as 21 CFR 312.310allows physicians to request compassionate use of experimental treatments through an investigational new drug pathway used for individual patients or for emergencies. These are designed to be used in these rare and special circumstances, Yancopoulos says. This is not the first time weve done compassionate use for these monoclonal antibodies. This is not a mechanism for widespread distribution.

Could Regenerons monoclonal antibody treatment become more widely available through the FDAs emergency use authorization (EUA) pathway?

Yes. Both Regeneron and Eli Lilly, which similarly reported encouraging preliminary clinical trial data last month from a single SARS-CoV-2 monoclonal antibody, are discussing the possibility of an EUA with FDA. Lilly reported signs that its antibody reduced the need for hospitalization, but as with Regeneron, too few participants have so far become seriously ill to reach a convincing conclusion to this critical question.

What's the evidence for using remdesivir in COVID-19 patients?

Remdesivir is an antiviral drug developed by Gilead Sciences, originally to treat the hepatitis C virus. It did not perform well against that pathogen but has been tried against Ebola and other viruses, after showing some activity in cells and animal models. The drug inhibits a viral enzyme used for replication of the pathogen. Earlier this year, it demonstrated a modest clinical benefit in a trial with hospitalized COVID-19 patients, leading FDA to grant Gilead an emergency use authorization for the drug. That EUA has since been expanded for use in patients with mild disease although its benefit in them is not clear. The drug has become widely used for COVID-19 patients despite continuing skepticism that it has a major clinical benefit. Since it and the monoclonal antibodies target different parts of the virus, administering them together may have a synergistic effect. One COVID-19 clinical trial is testing remdesivir and Lilly's antibody, for example.

Is the president receiving any other COVID-19 treatments?

The statement released today by the presidents physician said that in addition to the antibodies, Trump has been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin. That wording leaves unclear whether he was taking those substances before his diagnosed infection. Notably, the statement does not indicate whetherTrump was or is taking hydroxychloroquine, the antimalarial he controversially pushed as a COVID-19 treatment.

Famotidine has been suggested to be a treatment for COVID-19, but its also a popular heartburn remedy, sold widely under the name Pepcid. A clinical trial testing it in hospitalized COVID-19 patients in New York was not able to recruit enough patients to properly evaluate its impact. The Feinstein Institutes for Medical Research, which initiated that trial, released a statement today citing evidence it was helpful for COVID-19 but also saying, We have yet to prove [famotidines] efficacy. The institute says its eagerly awaiting FDA approval of a trial that will evaluate whether famotidine can help people who are not hospitalized.

*Updated, 3 October, 6 a.m.: Information about Trumps's use of remdesivir was added to the story.

The rest is here:
Here's what is known about Trump's COVID-19 treatment - Science Magazine

Related Post